Castle Biosciences (CSTL) financial statements
Castle Biosciences reported revenue of $344M in fiscal 2025, up 47.4% a year over 7 years.
Net income was -$24M and the operating margin -12.4%, against -16.8% in 2018.
Free cash flow was $28M.
The diluted share count rose 1421% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Castle Biosciences's 10-K filings with the SEC.
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $23M | $52M | $63M | $94M | $137M | $220M | $332M | $344M |
| Cost of revenue | $5M | $7M | $10M | $16M | $32M | $45M | $60M | $71M |
| Gross profit | $17M | $45M | $53M | $78M | $105M | $175M | $272M | $273M |
| Research and development | $5M | $7M | $13M | $30M | $45M | $54M | $52M | $52M |
| Selling, general and admin | $16M | $30M | $48M | $87M | $143M | $180M | $200M | $229M |
| Operating income | -$4M | $7M | -$7M | -$40M | -$73M | -$68M | $9M | -$43M |
| Interest expense | $2M | $5M | $3M | $1,000 | $17,000 | $11,000 | $577,000 | $86,000 |
| Income tax | $9,000 | $72,000 | $84,000 | -$9M | -$2M | $101,000 | $3M | -$5M |
| Net income | -$6M | $5M | -$10M | -$31M | -$67M | -$57M | $18M | -$24M |
| EPS (diluted) | -$5.33 | -$0.21 | -$0.54 | -$1.24 | -$2.58 | -$2.14 | $0.62 | -$0.83 |
| Diluted shares | 2M | 9M | 19M | 25M | 26M | 27M | 29M | 29M |
| Gross margin | 76.8% | 85.9% | 84.5% | 83.2% | 76.6% | 79.5% | 81.9% | 79.4% |
| Operating margin | -16.8% | 14.1% | -10.4% | -42.6% | -53.2% | -30.9% | 2.6% | -12.4% |
| Net margin | -27.9% | 10.2% | -16.4% | -33.3% | -49.0% | -26.1% | 5.5% | -7.0% |
Balance sheet
Fiscal years, from Castle Biosciences's 10-K filings with the SEC.
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $4M | $99M | $410M | $330M | $259M | $243M | $293M | $300M |
| Receivables | $12M | $15M | $13M | $17M | $23M | $38M | $51M | $43M |
| Inventory | $882,000 | $1M | $2M | $2M | $4M | $8M | $8M | $10M |
| Total current assets | $18M | $117M | $430M | $354M | $292M | $296M | $360M | $361M |
| Property, plant and equipment | $2M | $2M | $7M | $10M | $14M | $25M | $51M | $97M |
| Goodwill | — | — | — | $0 | $11M | $11M | $11M | $11M |
| Total assets | $22M | $120M | $439M | $463M | $447M | $453M | $531M | $579M |
| Total current liabilities | $7M | $15M | $21M | $25M | $36M | $48M | $49M | $69M |
| Long-term debt | $24M | $19M | $0 | — | — | $0 | $10M | $10M |
| Total liabilities | $32M | $35M | $24M | $51M | $48M | $62M | $75M | $108M |
| Shareholders' equity | -$57M | $85M | $416M | $412M | $399M | $391M | $456M | $471M |
| Net debt | $20M | -$74M | -$410M | -$330M | -$123M | -$99M | -$110M | -$107M |
Cash flow
Fiscal years, from Castle Biosciences's 10-K filings with the SEC.
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$12M | $7M | $10M | -$19M | -$42M | -$6M | $65M | $64M |
| Capital spending | $277,000 | $937,000 | $5M | $3M | $6M | $14M | $28M | $36M |
| Free cash flow | -$13M | $6M | $5M | -$22M | -$47M | -$19M | $37M | $28M |
| Stock-based compensation | $294,000 | $1M | $8M | $22M | $36M | $51M | $50M | $46M |
| Free cash flow margin | -55.2% | 11.7% | 8.2% | -23.9% | -34.5% | -8.8% | 11.0% | 8.2% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for CSTL.
Open CSTL in InvestinglyQuestions
What was Castle Biosciences's revenue in 2025?
$344M in fiscal 2025, from its 10-K filing.
How much free cash flow does Castle Biosciences generate?
$28M in fiscal 2025 (operating cash flow minus capital spending).
From Castle Biosciences's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.